Finalist
Let’s tALK Webinar Series for Takeda
Summary of work
The management of patients with ALK+ advanced non-small cell lung cancer (aNSCLC) can be daunting. A small patient population coupled with an evolving treatment landscape requires clinicians to keep uptodate with developments for the infrequent occasions that patients present.
In 2020, Takeda launched Alunbrig (brigatinib) as a first-line treatment option, having been available as a second-line option since 2018. Based on HCP insights into the challenges faced, Takeda developed the ‘Let’s tALK’ webinar series. Let’s tALK places an emphasis on peer-to-peer exchange of expertise. While an obvious approach would have been to heavily focus on delivering product message, Takeda met the needs of the community by offering education across the full patient pathway, including detailed consideration of competitor treatments. By having a broad remit, let’s tALK offers a balanced viewpoint, to deliver credible education to a range of HCPs, with the ultimate aim of improving patient outcomes.
There have been five Let’s tALK webinars, with peak attendance of 278. Benchmarks have consistently been surpassed with over 90% of attendees rating the webinars as relevant to educational needs with strong indications of changes in clinical practice based on attendance and 54% rating the series as better than competitor offerings.
Judges’ comments
The judges liked the use of audience archetypes in this entry as a means of structuring and delivering content. The entry involved a good cross-section of people and the multi-regional outreach was well covered.
